Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 6/2016

01-06-2016 | Leukemia (A Aguayo, Section Editor)

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Authors: Aharon Ronson, Ariella Tvito, Jacob M. Rowe

Published in: Current Oncology Reports | Issue 6/2016

Login to get access

Abstract

Patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis with less than 10 % of patients surviving 5 years. Most such patients cannot be rescued with currently available therapies, whatever the initial treatment they receive. Therefore, there is an urgent need for novel treatment options. Fortunately, over the past several years, an improved understanding of the biology of the disease has allowed the identification of rational molecular targets for therapeutic endeavors and the emergence of novel therapies has sparked great interest. This review will discuss the current treatment landscape for adult patients with relapsed and/or refractory ALL.
Literature
1.
2.
3.
Dombret H, Cluzeau T, Huguet F, Boissel N. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Report. 2014;9(2):158–64.CrossRef
4.
Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XІІ/ECOG E2993. Blood. 2005;106:3760–7.CrossRefPubMed
5.
Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRCUKALL12/ECOG2993 study. Blood. 2007;109:944–50.CrossRefPubMed
6.
Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed acute lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors and performance of stem cell transplantation. Blood. 2012;120(10):2032–41.CrossRefPubMed
7.
Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907–14.CrossRefPubMed
8.
Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–86.CrossRefPubMed
9.
10.
Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15(1):163–205.CrossRefPubMed
11.
Fielding AK. Current therapeutic strategies in adult lymphoblastic leukemia. Hematol Oncol Clin N Am. 2011;25:1255–79.CrossRef
12.
Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–8.CrossRefPubMedPubMedCentral
13.
Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analogue, is active in pediatric patients with advanced leukemia. Blood. 2004;103(3):784–9.CrossRefPubMed
14.
O’Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukemia. Br J Haematol. 2011;154(4):482–5.CrossRefPubMed
15.
Kantarjian HM, Gandhi V, Kozuch P, et al. Phase 1 clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21(6):1167–73.CrossRefPubMed
16.
Kantarjian HM, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379–86.CrossRefPubMed
17.
Faderl S, Gandhi V, O’Brien S, et al. Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105(3):940–7.CrossRefPubMed
18.
Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010;151(5):430–4.CrossRefPubMedPubMedCentral
19.•
Lee L, Fielding AK. Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. Clinical Medicine Insights: Oncology. 2012;6:85–100. A good early review of the emerging novel therapies in ALL.PubMedPubMedCentral
20.
Gokbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118(13):3504–16.CrossRefPubMed
21.•
Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol. 2014;10(3):483–94. A comprehensive review of the pharmacokinetics of vincristine and the rationale for liposomal formulas to reduce toxicities.CrossRefPubMed
22.
Weiden P, Wright S. Vincristine neurotoxicity. N Engl J Med. 1972;286:1369–70.PubMed
23.
Allen T, Cullis P. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Del Rev. 2013;65:36–48.CrossRef
24.
Boman NL, Bally BB, Cullis PR. Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy. J Liposome Res. 1995;5(3):523–41.CrossRef
25.
Webb MS, Harasym TO, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72:896–904.CrossRefPubMedPubMedCentral
26.
O’Brien S, Schiller G, Lister J, et al. High dose vincristine sulfate liposome injection for advanced, relapsed and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31(6):676–83.CrossRefPubMed
27.
Davis T, Farag SS. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine. Int J Nanomedicine. 2013;8:3479–88.PubMedPubMedCentral
28.••
Pathak P, Hess R, Weiss MA. Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature. Ther Adv Hematol. 2014;5(1):18–24. The definitive clinical study that led to the approval of liposomal vincristine for use in relapsed and refractory ALL.CrossRefPubMedPubMedCentral
29.
Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 2009;69(7):859–88.CrossRefPubMed
30.
McCormack PL. Bortezomib: a review in mantle cell lymphoma in previously untreated patients unsuitable for stem cell transplantation. BioDrugs. 2015;29(3):207–14.CrossRefPubMed
31.•
Xiao-Li D, Qi C. Recent advancements of bortezomib in acute lymphocytic leukemia treatment. Acta Haematologica. 2013;129:207–14. One of the few papers to describe the use of bortezomib in ALL.CrossRef
32.
Cortes J, Thomas D, Koller C, et al. Phase 1 study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;10(10):3371–6.CrossRefPubMed
33.
34.
Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15(481):504.
35.
Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005;88:1–50.CrossRefPubMed
36.
Ohanian M, Kantarjian H, Guy D, et al. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin’s lymphomas. Expert Opin Biol Ther. 2015;15(4):601–11.CrossRefPubMed
37.
Hinman LM, Hamann PR, Wallace R, Menendez AT, et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53:3336–42.PubMed
38.
Damle NK, Philip F. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Current Opinion in Pharmacology. 2003;3:386–90.CrossRefPubMed
39.
Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID, et al. Influence of CD33 expression levels and ITIM-dependent internalization of gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105:1295–302.CrossRefPubMed
40.
Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838–341.
41.
de Vries JK, Zwaan CM, De Bie M, Voerman JSA, den Boer ML, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26:255–64.CrossRefPubMed
42.
JF DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807–14.CrossRef
43.
DiJoseph JF, Popplewell A, Tickle S, et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother. 2005;54:11–24.CrossRefPubMed
44.
DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res. 2004;10:8620–9.CrossRefPubMed
45.
DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK. Preclinical anti-tumor activity of antibody targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 2011;67(4):741–9.CrossRefPubMed
46.
DiJoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240–5.CrossRefPubMed
47.
Advani A, Gine E, Gisselbrecht C, et al. Preliminary report of a Phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin’s lymphoma. ASH Annual Meeting Abstracts (abstract 230). Blood. 2005;106:70a.
48.
Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a Phase 1 study. J Clin Oncol. 2010;28(12):2085–93.CrossRefPubMed
49.
Goy A et al. Inotuzumab ozogamicin (INO, CMC-544) in patients with indolent B-cell NHL refractory to rituximab. 11th International Conference of Malignant Lymphoma, Abstract 069. Lugano, Switzerland, 15–18 June 2011
50.
Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–11.CrossRefPubMed
51.
Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36.CrossRefPubMedPubMedCentral
52.
DeAngelo D, Stock W, Petersdorf S, et al. Weekly inotuzumab ozogamicin in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia. Blood. 2012;120 Suppl 1:2612.
53.••
De Angelo DJ, Stelljes M, Martinelli G, et al. Efficacy and safety of inotuzumab ozogamicin versus standard of care in salvage 1 or 2 patients with acute lymphoblastic leukemia (ALL): an ongoing global phase 3 study. EHA 2015 Abstract#LB2073. Although only an abstract form, this publication may be the forerunner of the most important study demonstrating remarkable efficacy of inotuzumab ozogamicin.
54.
Le Jeune C, Thomas X. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur J Haematol. 2015;94(2):99–108.CrossRefPubMed
55.•
Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Reviews. 2012;26:25–32. An excellent basic review of novel chemoimmunotherapeutic agents in ALL.CrossRefPubMed
56.••
Jabbour E, O’Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125:4010–6. An important review of monoclonal antibodies in ALL.CrossRefPubMed
57.
Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880–9.CrossRefPubMedPubMedCentral
58.
Kochuparambil ST, Litzow MR. Novel antibody therapy in acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2014;9:165–73.CrossRefPubMed
59.
Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as a single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–55.CrossRefPubMed
60.
Jabbour E, Kantarjian H, Thomas D, et al. Phase 2 study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (abstract). J Clin Oncol. 2014 Abstract 2065.
61.
Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituzimab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053–61.CrossRefPubMedPubMedCentral
62.
Advani A, MC Donough S, Coutre S, et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia. Brit J Haematol. 2014;165:504–9.CrossRef
63.
Chevallier P, Huguet F, Raffoux E, et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase 2 study. Haematologica. 2015;100:128–31.CrossRef
64.
Warner JL, Arnason J. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rationale use. Ther Adv Hematol. 2012;3(6):375–89.CrossRefPubMedPubMedCentral
65.
Silva-Fernandez L, Loza E, Martinez-Taboada VM, et al. Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum. 2014;43(4):542–57.CrossRefPubMed
66.
67.
Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106:2645–51.CrossRefPubMed
68.
Angiolillo AL, Yu AL, Reaman G, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children’s Oncology Group report. Pediatr Blood Cancer. 2009;53:978–83.CrossRefPubMedPubMedCentral
69.
Stock W, Sanford B, Losanski G, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase 1 results of a Cancer and Leukemia Group B study (CALGB 10102). Blood. 2009;114(1):838.
70.
Gorin NC, Isnard F, Garderet L, et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of phase 2 study. Eur J Hematol. 2013;91(4):315–21.
71.
Weiland J, Elder A, Forster V, Heidenreich O, et al. CD19: a multifunctional immunological target molecule and its implications for bilineage acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:1144–8.CrossRefPubMed
72.
Scheuermann RH, Racila E, et al. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18:385–97.CrossRefPubMed
73.
Klener Jr P, Otahal P, Lateckova L, Klener P. Immunotherapy approaches in cancer treatment. Curr Pharm Biotechnol. 2015;16(9):771–81.CrossRefPubMed
74.
Advani AS (2013). New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors. Hematol Am Soc Hematol Educ Program 2013:131–137.
75.••
Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–8. The first paper to demonstrate significant clinical activities of the BiTE antibodies.CrossRefPubMed
76.••
Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–7. Important description of the cytokine release system following some of the novel anti-CD19 therapies.CrossRefPubMedPubMedCentral
77.
Topp M, Gokbuget N, Zugmaier G, et al. Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. J Clin Oncol. 2012;30:6500.
78.••
Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia: a multicenter, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. Very important paper on the use of blinatumomab for relapsed or refractory ALL describing the study that led to this agent.CrossRefPubMed
79.••
Maude SL, Teachey DT, Porter DL, et al. CD 19 targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–23. Very important paper summarizing the data for CAR-T therapy in ALL.CrossRefPubMedPubMedCentral
80.
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86(24):10024–8.CrossRefPubMedPubMedCentral
81.••
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. A detailed state-of-the-art review of CAR-T cells in leukemia.CrossRefPubMedPubMedCentral
82.
Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.CrossRefPubMedPubMedCentral
83.
Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28.CrossRefPubMed
Metadata
Title
Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
Authors
Aharon Ronson
Ariella Tvito
Jacob M. Rowe
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Oncology Reports / Issue 6/2016
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-016-0519-8

Other articles of this Issue 6/2016

Current Oncology Reports 6/2016 Go to the issue

Melanoma (RJ Sullivan, Section Editor)

Cell Cycle Regulation and Melanoma

Cardio-oncology (EH Yang, Section Editor)

Exercise Training in Cancer Survivors

Cardio-oncology (EH Yang, Section Editor)

Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management

Cardio-oncology (EH Yang, Section Editor)

Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?

Integrative Care (C Lammersfeld, Section Editor)

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

Sarcomas (SR Patel, Section Editor)

Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits